Skip to content

Study · Animal study (in vivo) · rat · 1989

3 results

[Anticonvulsive properties of peptide ACTH4-7 pro-gly-pro detected in amygdaloid kindling and audiogenic epilepsy in rats].

Chepurnov SA, Chepurnova NE, Artiukhova MV, Kuznetsova EIu, Nezavibat'ko VN

Biulleten' eksperimental'noi biologii i meditsiny1 Jun 1989Cited by 1 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, ACTH4-7 pro-gly-pro (semax) had an anticonvulsant profile in kindling and audiogenic epilepsy models. The abstract gives no direction or size.

    In plain wordsIn rats, ACTH4-7 pro-gly-pro (semax) showed anticonvulsant effects in epilepsy models.

    Peptide
    Semax
    Outcome
    Direction not reportedAnticonvulsant profile in amygdaloid kindling and audiogenic epilepsy
    Study

    ratn: not reported in source

    Amygdaloid kindling and audiogenic epilepsy
    Outcome group
    Seizures · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    ACTH4-7 pro-gly-pro had an anticonvulsant profile.
    2 context sentences
    Summary · context
    Effects of the ACTH4-7 pro-gly-pro, calcium valproate ("Germed", DDR) and nembutal on kindling preparation and audiogenic epilepsy were investigated.
    Summary · context
    Development of after-discharges in response to repeated amygdaloid electrical stimulation was assessed in normal rats and in rats susceptible to audiogenic epilepsy (KM line of rats).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats, ACTH4-7 pro-gly-pro (semax) decreased the seizure threshold in the audiogenic epilepsy test.

    In plain wordsIn rats, ACTH4-7 pro-gly-pro (semax) lowered the seizure threshold in an audiogenic epilepsy test.

    Peptide
    Semax
    Outcome
    DecreaseSeizure threshold in the audiogenic epilepsy test
    Study

    ratn: not reported in source

    Audiogenic epilepsy
    Outcome group
    Seizures · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    ACTH4-7 pro-gly-pro decreased seizure threshold in the audiogenic epilepsy test
    2 context sentences
    Summary · context
    Effects of the ACTH4-7 pro-gly-pro, calcium valproate ("Germed", DDR) and nembutal on kindling preparation and audiogenic epilepsy were investigated.
    Summary · context
    Development of after-discharges in response to repeated amygdaloid electrical stimulation was assessed in normal rats and in rats susceptible to audiogenic epilepsy (KM line of rats).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats, ACTH4-7 pro-gly-pro (semax) did not prevent motor convulsions in the audiogenic epilepsy test.

    In plain wordsIn rats, ACTH4-7 pro-gly-pro (semax) did not prevent motor convulsions in an epilepsy test.

    Peptide
    Semax
    Outcome
    No significant changeMotor convulsions in audiogenic epilepsy
    Study

    ratn: not reported in source

    Audiogenic epilepsy
    Outcome group
    Seizures · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    ACTH4-7 pro-gly-pro decreased seizure threshold in the audiogenic epilepsy test, but did not prevent the motor convulsions.
    2 context sentences
    Summary · context
    Effects of the ACTH4-7 pro-gly-pro, calcium valproate ("Germed", DDR) and nembutal on kindling preparation and audiogenic epilepsy were investigated.
    Summary · context
    Development of after-discharges in response to repeated amygdaloid electrical stimulation was assessed in normal rats and in rats susceptible to audiogenic epilepsy (KM line of rats).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:40 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.